Page
What Is Xgeva?Xgeva® (denosumab) is a monoclonal antibody that prevents bone complications in myeloma patients. Our bodies have a delicate balance between cells that build bone (osteoblasts) and cells that break down bone (osteoclasts). For myeloma patients, signals sent by cancerous myeloma cells…
Videos
FasTCAR-T Cells for High-Risk Myeloma
Dr. Juan Du presents a study that assessed the safety and feasibility of GC012F CAR-T therapy in the frontline setting for high-risk, transplant-eligible newly diagnosed multiple myeloma patients
Abstract title:
Phase I Open-Label Single-Arm Study of…
Videos
BloodFlow: A New Next Generation Flow (NGF) Blood Test
Myeloma expert Dr. Brian G.M. Durie discusses the new NGF blood test called BloodFlow and how this blood test can be used to detect minimal residual disease (MRD) at a sensitive level.
The BOTTOM LINE: This…
Page
Corporate and foundation support is critical to advance the IMF’s mission of improving the quality of patients’ lives while working toward prevention and a cure. Partnering with the IMF is a wise investment in the future and provides value for your company. The IMF can guide your giving strategy so…
Event
Many of you know of my journey with MM from my Diagnosis in 2008. In 2008 and 09, I was in a wheelchair and then a walker. Starting in 2010 I was using Nordic Walking sticks to get around and finally got back on the bicycle in late summer. In 2011 I took my first bicycle trip to…
Videos
Mass Spectrometry and Next-Generation Flow
Myeloma expert Dr. Brian G.M. Durie discusses how mass spectrometry and next-generation flow can be used to predict the length of remission.
The BOTTOM LINE: Mass spectrometry and next-generation flow can be used to…
Videos
Myeloma Risk Factors By Race and Ethnicity
Dr. Tondre Buck presents an abstract on real-world multiple myeloma risk factors and outcomes by race/ethnicity in the United States.
Abstract title:
Real-World Multiple Myeloma Risk Factors and Outcomes By Race/Ethnicity in the United States…
Page
What Is Minimal Residual Disease Testing?MRD testing for myeloma refers to the detection of very small numbers of myeloma cells that may remain in the body after treatment. These cells are often so few that they don't cause symptoms and are…
Videos
Bispecifics Part 4: The Science of Bispecific Antibodies
What are current bispecific antibodies and how do they work?
In this video, IMF Chief Medical Officer Dr. Joseph Mikhael explains how both monoclonal antibodies and bispecific antibodies are designed to specifically attach to a precise…
Videos
Bispecifics Part 3: The Pros and Cons of Bispecifics
What are the pros and cons of bispecific therapies?
In this video, IMF Chief Medical Officer Dr. Joseph Mikhael discusses the main benefits of bispecific antibody therapies, such as the ability to administer these drugs off the shelf, their…
Videos
Bispecifics Part 2: Monoclonal and Bispecific Antibodies
What are the differences among monoclonal antibodies, CAR T-cell therapies, and bispecific antibodies?
In this video, IMF Chief Medical Officer Dr. Joseph Mikhael defines and explains the differences between monoclonal antibodies and…
Videos
Bispecific Antibodies Part 1: Immune System and Immunotherapy Basics
What is immunotherapy?
In this video, IMF Chief Medical Officer Dr. Joseph Mikhael explains the basics of the immune system, including Natural Kill (NK) cells, and T cells. He discusses antibody immunity, or the “…
Videos
Talquetamab in Relapsed Myeloma Patients
Dr. Ajai Chari presents an abstract on Talquetamab in patients with relapsed refractory multiple myeloma.
Abstract title:
Talquetamab, a G Protein-Coupled Receptor Family C Group 5 Member D x CD3 Bispecific Antibody, in Patients with Relapsed/…
Videos
Idecabtagene Vicleucel in Post-Stem Cell Transplant Myeloma Patients
Dr. Saad Usmani presents an abstract on the efficacy and safety of Idecabtagene Vicleucel in clinical high-risk multiple myeloma patients with early relapse after frontline autologous stem cell transplantation. …
Videos
When Should MGUS Patients Undergo Bone Marrow Biopsy?
Myeloma expert Dr. Brian G.M. Durie discusses how the IMF’s iStopMM study results presented at the 2022 American Society of Hematology (ASH) meeting may help predict when a bone marrow biopsy is needed.
…
Videos
Dr. Gary Schiller, UCLA David Geffen School of Medicine, presents the results of once weekly Selinexor, Carfilzomib and Dexamethasone in triple class refractory multiple myeloma.
Background:
Selinexor, an oral exportin-1 inhibitor, is approved for the treatment of relapsed/refractory multiple…
News Article
GMAN Meeting at the American Society of Hematology 2022
On Thursday, December 15th, 2022, more than 30 members of the Global Myeloma Action Network (GMAN) came together for a virtual meeting to review the key outputs of the American Society of Hematology (ASH) conference held in New…
Page
A Message From IMF President and CEO, Yelak Biru
Watch IMF President and CEO—as well as 27-year multiple myeloma survivor—Yelak Biru reflect on the impact of the IMF in 2022 and share his vision for the future.
Videos
Chronic Kidney Disease in MGUS Patients
Dr. Thorir Einarsson Long presents an abstract to compare the prevalence of chronic kidney disease in individuals with and without monoclonal gammopathy of undetermined significance in a large, prospective, screened, population-based cohort.
Abstract…
Videos
Circulating Tumor Cells in iStopMM Study
Dr. Sigrún Thorsteinsdóttir presents a study on circulating tumor plasma cells in peripheral blood and its correlation to progression from smoldering multiple myeloma to multiple myeloma.
Abstract title:
Circulating Tumor Plasma Cells in the…
Videos
Dr. Paul Richardson, Dana-Farber Cancer Institute, presents an abstract on Isatuximab plus Pomalidomide/Low-Dose Dexamethasone versus Pomalidomide/Low-Dose Dexamethasone in patients with Relapsed/Refractory Multiple Myeloma (ICARIA-MM).
Background:
Based on the primary analysis of the Phase 3…
Videos
Dr. Noemi Puig, University of Salamanca, discusses an abstract on the clinical impact of Next Generation Flow in bone marrow vs QiP-Mass Spectrometry in peripheral blood to assess Minimal Residual Disease in newly diagnosed multiple myeloma patients.
Background:
GEM2014MAIN is a phase 3,…
Videos
Mezigdomide Combined with Dexamethasone in Myeloma Patients
Dr. Paul Richardson presents the preliminary results from the dose-expansion phase of the CC-92480-MM-001 trial studying Mezigdomide combine with Dexamethasone in relapsed/refractory multiple myeloma patients
Abstract title:…
Videos
Measuring MRD in Myeloma Patients with Bloodflow Method
Dr. Laura Notarfranchi presents the results of ultra-sensitive assessment of Measurable Residual Disease (MRD) in Peripheral Blood (PB) of multiple myeloma patients using Bloodflow
Abstract title:
Ultra-Sensitive Assessment of…
Videos
No Link Found Between Autoimmune Disease and MGUS
Dr. Ingigerdur Sverrisdottir presents an abstract on the relationship between monoclonal gammopathy of undetermined significance (MGUS) and autoimmune diseases.
Abstract title:
Autoimmune Diseases Are Not Associated with Monoclonal…
Videos
iStopMM Results of Hypercalcemia in Patients with MGUS
Dr. Ástrún Helga Jónsdóttir presents the results of an iStopMM study regarding hypercalcemia in individuals with Monoclonal Gammopathy of Undetermined Significance (MGUS).
Abstract title:
Hypercalcemia in Individuals with…
Videos
KRd vs VRd as Induction Therapy for Myeloma
Dr. Carlyn Tan presents the results of a study on Carfilzomib, Lenalidomide and Dexamethasone (KRd) Vs Bortezomib, Lenalidomide, and Dexamethasone (VRd) as induction therapy in newly diagnosed High-Risk Multiple Myeloma (HR-NDMM).
Abstract title…
Videos
Racial and Ethnic Differences Among CAR T-cell Therapy for Multiple Myeloma Patients
Dr. Lauren Peres presents an abstract on the racial and ethnic differences in clinical outcomes among multiple myeloma patients treated with CAR T-cell therapy.
Abstract title:
Racial and Ethnic…
Videos
Multiomics profiling of Measurable Residual Disease (MRD) in Myeloma
Camila Guerrero presents an abstract on multiomics profiling of Measurable Residual Disease (MRD) for understanding the biology of ultra-drug resistance in multiple myeloma
Abstract title:
Multiomics Profiling of…
Videos
Can Circulating Tumor DNA Improve Identification of High-Risk Myeloma Patients?
Dr. Sridurga Mithraprabhu presents the results of a study to find out if circulating RAS/RAF and DNA-Repair gene mutations associates with high-Risk/treatment resistance in primary refractory multiple myeloma…
Videos
GEM-CESAR Curative Strategy for High-Risk Smoldering Multiple Myeloma
Dr. Maria Victoria Mateos presents curative strategy (GEM-CESAR) for high-risk smoldering myeloma (SMM), a post-hoc analysis of sustained undetectable measurable residual disease (MRD).
Abstract title:
Curative…
Videos
In this iStopMM study Jon Þórir Oskarsson presents the results of determining hemodilution in diagnostic bone marrow samples in multiple myeloma and its precursors by Next-Generation Flow Cytometry (NGF).
Background:
A major limitation for quantification of bone marrow (BM) plasma cells (PC)…
Videos
The Effects of a Combination of Teclistamab, Subcutaneous Daratumumab, and Lenalidomide in Myeloma
Dr. Emma Searle presents the results of Cohort E of MajesTEC-2 studying the effects of Teclistamab in combination with subcutaneous Daratumumab and Lenalidomide in patients with multiple myeloma…
Videos
The Impact of Hispanic Ethnicity on Multiple Myeloma
Dr. Kara Cicero presents a study on the impact of Hispanic ethnicity on disease characteristics in multiple myeloma
Abstract title:
The Impact of Hispanic Ethnicity on Disease Characteristics in Multiple Myeloma
Purpose of the…
Videos
Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone in High-Risk Myeloma
Dr. Katja Weisel presents the results of Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone (Isa-KRd) in patients with high-risk newly diagnosed multiple myeloma
Abstract title:
Isatuximab, Carfilzomib,…
Videos
Forimtamig's Effect on T-cells in Relapsed Myeloma Patients
Dr. Carmelo Carlo-Stella presents the updated intravenous and subcutaneous results from a Phase I dose escalation study of Forimtamig, a GPRC5DxCD3 T-cell engaging bispecific antibody with relapsed/refractory multiple myeloma patients…
Videos
Phase 1 Clinical Study of the BCMA Nex T CAR T-Cell Therapy
Dr. Luciano Costa presents the results of the first phase 1 clinical study of the B-Cell Maturation Antigen (BCMA) Nex T Chimeric Antigen Receptor (CAR) T Cell therapy CC-98633/BMS-986354 in patients with Relapsed/Refractory Multiple…
Videos
Study on Dynamic Frailty Risk Assessment in Myeloma
Dr. Hira Mian presents a study examining the need for dynamic frailty assessment among older adults with multiple myeloma
Abstract title:
Need for Dynamic Frailty Risk Assessment Among Older Adults with Multiple Myeloma: A Population-…
Videos
Dr. Brian G.M. Durie discusses important takeaways relating to multiple myeloma from the annual American Society of Hematology (ASH) conference
…
Videos
ASH 2022: Making Sense of Treatment
In the IMWG Conference Series, “Making Sense of Treatment,” leading myeloma experts discuss the latest myeloma news from the 64th American Society of Hematology Annual Meeting in December 2022
Moderated by IMF Chairman of the Board Dr. Brian G.M.…
Videos
Study of Modakafusp Alfa in Relapsed Multiple Myeloma Patients
Dr. Dan Vogl presents the final results from the phase 1/2 first-in-human study of Modakafusp Alfa, in patients with relapsed/refractory myeloma
Abstract title:
Final Results from the First-in-Human Phase 1/2 Study of…
Videos
What is the Pandemic's Impact on Myeloma Management and Treatment?
Dr. Joshua Richter presents the results of pandemic’s influence on multiple myeloma management, treatment patterns, and provider contact with patients based from insights from the Connect® MM Registry
Abstract title:
Impact…
Videos
SARS-CoV-2 Vaccination's Impact on the Progression of MGUS to MM
Dr. Robert Palmason discusses the results of a study investigating if SARS-CoV-2 vaccination impacts the risk of progression from MGUS to multiple myeloma
Abstract Title:
105 Sars-Cov-2 Vaccinations Do Not Lead to Progression…
Videos
Real World Outcomes of Myeloma Patients Treated with BCMA-Targeted Therapy Followed by Ide-Cel
Dr. Christopher Ferreri, MD Anderson Cancer Center, Houston, TX, discusses a study that evaluated the real-world outcomes for patients treated with standard of care ide-cel after having previously…
Videos
The iStopMM Study on Transient M-Proteins and the Use of Mass Spectometry for the Evaluation of Monoclonal Proteins
Dr. Robert Palmason discusses the epidemiology of individuals with transient M-proteins in the prospective screening manner based on the Iceland Screens, Treats, or Prevents…
Videos
The Effects of Arginine Deprivation on Proteasome Inhibitor Resistance in Multiple Myeloma Patients
Dr. Alessandra Romano discusses an abstract exploring the effects of arginine deprivation to proteasome inhibitor resistance in multiple myeloma via increased lactate release and metabolic…
Videos
Dr. Brian GM Durie, International Myeloma Foundation, presents an abstract on the efficacy and safety bortezomib-lenalidomide-dexamethasone based on age.
Background:
The SWOG S0777 phase 3 randomized controlled trial demonstrated that treatment with bortezomib-lenalidomide-dexamethasone (VRd…
Videos
Updated Results of the IMF ASCENT Trial Were Presented at the 2022 ASH Meeting
Myeloma expert Dr. Brian G.M. Durie discusses the International Myeloma Foundation’s Black Swan Research Initiative-funded ASCENT trial—one of the myeloma “cure” trials funded by the IMF.
“We are quite…
Videos
The Impact of Socioeconomic Status on the Progression and Survival Rates of Multiple Myeloma
Dr. Leon Bernal-Mizrachi discusses a study that examines the impact of socioeconomic status on adherence to oral medications, survival without progression, and overall survival in multiple myeloma…